相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systematic transcriptomic and phenotypic characterization of human and murine cardiac myocyte cell lines and primary cardiomyocytes reveals serious limitations and low resemblances to adult cardiac phenotype
Zsofia Onodi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2022)
Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Lindsay N. Moreland-Head et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2021)
Somatostatin and Its Receptors in Myocardial Ischemia/Reperfusion Injury and Cardioprotection
Imre Voeroes et al.
FRONTIERS IN PHARMACOLOGY (2021)
The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety
Charles E. Leonard et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion
Gabor B. Brenner et al.
CELLS (2020)
A Comorbidity Model of Myocardial Ischemia/Reperfusion Injury and Hypercholesterolemia in Rat Cardiac Myocyte Cultures
Andras Makkos et al.
FRONTIERS IN PHYSIOLOGY (2020)
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
Jianhong Zhu et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Decorin Protects Cardiac Myocytes against Simulated Ischemia/Reperfusion Injury
Renata Gaspar et al.
MOLECULES (2020)
Calcium Ionophore-Induced Extracellular Vesicles Mediate Cytoprotection against Simulated Ischemia/Reperfusion Injury in Cardiomyocyte-Derived Cell Lines by Inducing Heme Oxygenase 1
Peter Pecan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Cardioprotective Effect of Novel Matrix Metalloproteinase Inhibitors
Kamilla Gomori et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications
Peter Ferdinandy et al.
EUROPEAN HEART JOURNAL (2019)
Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats
Poonam Giri et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
Igho J. Onakpoya et al.
BMC MEDICINE (2016)
Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis
Igho J. Onakpoya et al.
CRITICAL REVIEWS IN TOXICOLOGY (2016)
Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats
Krisztina Kiss et al.
PHARMACOLOGICAL RESEARCH (2016)
Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats
Xin Zhou et al.
DRUG METABOLISM AND DISPOSITION (2016)
Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial
H. Florez et al.
DIABETES OBESITY & METABOLISM (2015)
Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis
Yu Lu et al.
JOURNAL OF DIABETES INVESTIGATION (2015)
Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin
Ling He et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Interaction of Risk Factors, Comorbidities, and Comedications with Ischemia/Reperfusion Injury and Cardioprotection by Preconditioning, Postconditioning, and Remote Conditioning
Peter Ferdinandy et al.
PHARMACOLOGICAL REVIEWS (2014)
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Kenneth W. Mahaffey et al.
AMERICAN HEART JOURNAL (2013)
Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
Richard G. Bach et al.
CIRCULATION (2013)
Effect of Hypoglycemic Agents on Ischemic Preconditioning in Patients With Type 2 Diabetes and Symptomatic Coronary Artery Disease
Rosa Maria Rahmi et al.
DIABETES CARE (2013)
Mechanisms responsible for beneficial and adverse effects of rosiglitazone in a rat model of acute cardiac ischaemiareperfusion
Siripong Palee et al.
EXPERIMENTAL PHYSIOLOGY (2013)
Rosiglitazone induces arrhythmogenesis in diabetic hypertensive rats with calcium handling alteration
Ting-I Lee et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
A new Comparative Effectiveness assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone
Richard Tannen et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
The Lambeth Conventions (II): Guidelines for the study of animal and human ventricular and supraventricular arrhythmias
Michael J. Curtis et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Effect of rosiglitazone on rabbit model of myocardial ischemia-rep effusion injury
Xia-Qing Gao et al.
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE (2013)
The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate
Himanshu Naik et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Thiazolidinedione Drugs Promote Onset, Alter Characteristics, and Increase Mortality of Ischemic Ventricular Fibrillation in Pigs
Mohammad Sarraf et al.
CARDIOVASCULAR DRUGS AND THERAPY (2012)
Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki Rats
Wei Gao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart
Siripong Palee et al.
EXPERIMENTAL PHYSIOLOGY (2011)
Simultaneous Determination and Pharmacokinetic Study of Metformin and Rosiglitazone in Human Plasma by HPLC-ESI-MS
Lingyun Chen et al.
JOURNAL OF CHROMATOGRAPHIC SCIENCE (2011)
Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury
Yajing Wang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
Steven E. Nissen et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Adiponectin An Indispensable Molecule in Rosiglitazone Cardioprotection Following Myocardial Infarction
Ling Tao et al.
CIRCULATION RESEARCH (2010)
Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway
Xue-Jiao Zhang et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2010)
Effect of ciprofloxacin and ibuprofen on thein vitro Metabolism of rosiglitazone and oral pharmacokinetics of rosiglitazone in healthy human volunteers
J. N. Suresh Kumar et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2010)
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
David J. Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature
Maria A. Potenza et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Changes in the Pharmacokinetics of Rosiglitazone, a CYP2C8 Substrate, When Co-Administered with Amlodipine in Rats
Seon Hwa Kim et al.
BIOMOLECULES & THERAPEUTICS (2009)
The PPAR-γ agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation
H. Kilter et al.
DIABETES OBESITY & METABOLISM (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts
Gabriella F. Kocsis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy
Wolfgang C. Winkelmayer et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs
L. Lu et al.
DIABETOLOGIA (2008)
Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method
Masahiro Abe et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Dose translation from animal to human studies revisited
Shannon Reagan-Shaw et al.
FASEB JOURNAL (2008)
Rosiglitazone is cardioprotective in a murine model of myocardial I/R
Jan Mersmann et al.
SHOCK (2008)
Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning
Peter Ferdinandy et al.
PHARMACOLOGICAL REVIEWS (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris
Whady Hueb et al.
CORONARY ARTERY DISEASE (2007)
Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK
Behzad Molavi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury
TL Yue et al.
DIABETES (2005)
Simplified method for determination of rosiglitazone in human plasma
MW Hruska et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2004)
Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects
JY Park et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects
JY Park et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans
KA Kim et al.
BIOMEDICAL CHROMATOGRAPHY (2004)
The PPARγ-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction
CA Lygate et al.
CARDIOVASCULAR RESEARCH (2003)
Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size
NS Wayman et al.
FASEB JOURNAL (2002)
In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone
TL Yue et al.
CIRCULATION (2001)
The effect of acarbose on the pharmacokinetics of rosiglitazone
AK Miller et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
分享论文
